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Abstract
Results and new hypotheses in animal models often stimulate development of new
paradigms in how we view rheumatoid arthritis (RA). The complexity of RA does, however,
eventually lead to the rejection of these hypotheses. Here, it is argued that the large number
of so-far described animal models, when taken together, also reveals a complex disease.
Fortunately, detailed study of each of the animal models will reveal this complexity, and may
also be helpful in elucidating the complexity of the human disease. Benoist and Mathis [1]
recently contributed a new animal model in which an autoimmune response to a ubiquitous
antigen leads to an antibody-mediated inflammatory attack in the joints. It is argued that this
new model, as with other animal models, is unlikely to explain RA, but it will add to the tools
available to reveal the complexity of RA.
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Introduction
RA as diagnosed by the American Rheumatism College
(ARC) criteria is a common disease, estimated to affect
0.5 to 1% of the world’s population. Its relatively high fre-
quency is evidence of a complex etiology and pathogene-
sis. RA is probably not one disease but, rather, a
syndrome caused by several widely different pathologic
processes. In this respect, RA could be likened to
headache. No one would seriously think of trying to find a
single explanation for headache. Rather, widely divergent
causes, such as stress, migraine, or brain tumors, would
quite rapidly be seen to be associated with quite different
diseases. Similarly, it may be time to start thinking of a
variety of different pathways leading to RA rather than
searching for one single explanation.
Need for variety of animal models
Likewise, more than one animal model for RA is needed.
More and more kinds of manipulation, genetic or environ-
mental, lead to arthritis in experimental animals. Thus,
arthritis can be induced by the injection of live bacteria,
such as Staphylococcus aureus [2] or Borrelia burgdorferi
[3]; of bacterial cell-wall fragments, such as in streptococ-
cal-induced arthritis [4] and in mycobacterium adjuvant-
induced arthritis [5], or of purified bacterial products such
as lipopolysaccharide [6] or muramyl dipeptide [7]. Arthri-
tis can also be induced by the injection of various exoge-
nous or endogenous oils permeable in cell membranes,
such as mineral oil, pristane, squalen, or C16-C17 fatty
acids [8–12], or by immunization with ubiquitous antigens
such as C1q [13] or gp39 [14], or with cartilage proteinsArthritis Research    Vol 2 No 3 Holmdahl
such as type II collagen [15], type XI collagen [16], carti-
lage oligomeric matrix protein [17], aggrecan [18], or
aggrecan link protein [19]. Arthritis can also develop after
induction of immune complexes in the joint [20], after
transfer of cartilage-specific antibodies [21], or after trans-
fer of activated T cells [22]. Moreover, it may develop
during the induction of a graft-versus-host disease. Arthri-
tis also develops spontaneously in normal inbred strains
[23–25] or in genetically manipulated strains that overex-
press foreign proteins, such as the human T cell leukemia
virus-I glycoprotein [26,27], molecules of the human major
histocompatibility complex [28], or inflammatory cytokines
such as tumor necrosis factor alpha [29]. Adding to this
list, it has now been reported that expression of a T-cell
receptor encoding for glucose-6-phosphate isomerase
(GPI) will lead to arthritis through the production of anti-
bodies specific for the same antigen [30].
All these models constitute an extremely valuable asset for
the analysis of different pathways leading to arthritis. Most
of these models use different arthritogenic pathways, and
there are arguments in support of the existence of each of
them for studies of RA.
Uses and limitations of the new GPI model
The newly described model in which antibodies specific
for GPI induce acute arthritis adds to our arsenal and will
be very useful for analyzing downstream mechanisms
leading to arthritis. Although there is no evidence that GPI
antibodies are found in humans, the availability of antibod-
ies that readily induce arthritis is useful for understanding
effector mechanisms. Furthermore, the main component of
acute arthritis in the widely used collagen-induced arthritis
model most likely mimics the same pathway [21,31–33].
An essential part is mediated by antibodies binding to the
cartilage surface and through complement and macro-
phage IgGFc-receptor-dependent pathways initiating
arthritis in the joints.
The descriptions of the arthritides induced in the GPI-anti-
body model and in the type II collagen-antibody model do
not seem to differ in any essential point, although further
study will probably reveal some differences. One differ-
ence is certainly the target epitope. The epitopes in the
type II collagen-antibody model are definitely type II colla-
gen in the cartilage [34,35], though the precise epitopes
and mechanisms are not fully clarified, whereas in the GPI
model the target epitope in situ has not yet been demon-
strated. GPI may be exposed extracellularly in the joints, or
there may be a joint cross-reactive neo-epitope that
attracts the binding of the antibodies.
It is less likely that the GPI model will provide information
on the upstream initiation of arthritis. By chance, resear-
chers have found many starting points for the triggering of
arthritis in animal models, as mentioned above. The
upstream events, or etiology, of arthritis are likely to be
more divergent than the downstream effects that are
defined by the ARC criteria. It seems more fruitful to find
the most important springs by starting downstream and
following the river upstream.
Need for a new paradigm
It is time to change the paradigm for our thinking about the
causes of RA. I certainly agree that pathways involving
pathogenic antibodies have more recently been lost sight
of in RA research and that lessons from the collagen-
induced arthritis model, as well as from the more recently
described GPI model, should be taken into account, par-
ticularly as corresponding anti-type II collagen antibody
reactivities in humans have been identified [36,37].
However, there have been some disappointments when
premature or misinterpreted findings from animal models
have been seen as offering an explanation for RA: the
induction of arthritis with T cells reactive to mycobac-
terium heat-shock proteins, a pathogenic oligoclonal T-cell
repertoire induced by superantigens, regulatory effects by
class II molecules, oral bystander vaccination, and carti-
lage-specific T cells primed in the joints, just to mention
some examples.
Conclusion
It is time to accept that RA is a complex disease with mul-
tiple causes and pathways. Recent advances will now
enable us to address these complexities and put forward
new hypotheses. Particularly exciting is the possibility of
understanding complex diseases through their genetic
susceptibility [38–40] – why certain subtypes of RA
develop in some but not other individuals due to their
genetic makeup and their environmental exposure. Differ-
ent diseases, with different pathways, will eventually be
identified in what we today call ‘RA’. There are strong
reasons to believe that the genetic makeup and the selec-
tive forces leading to arthritis are conserved between
rodents and humans. Furthermore, rodents can be used
to express the relevant human genes and test their impor-
tance [41–43]. Animal models such as this with well-
characterized, testable pathways are excellent tools in
this endeavor, and the GPI model is an important addition
to the arsenal.
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